But surprisingly, SRSF3 is negatively correlated with most immune checkpoints of tumors such as BRCA, GBM, LGG, and TGCT, suggesting that SRSF3 may play a negative regulatory role in tumor immunity (Figure S2C). Here, SRSF3 is linked to neoplasm.